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Available online 28 November 2016Staphylococcus aureus infections of the skin and soft tissue pose amajor concern to public health, largely owing to
the steadily increasing prevalence of drug resistant isolates. As an alternative mode of treatment both bacterio-
phage endolysins and bacteriocins have been shown to possess antimicrobial efﬁcacy against multiple species
of bacteria including otherwise drug resistant strains. Despite this, the administration and exposure of such an-
timicrobials should be restricted until required in order to discourage the continued evolution of bacterial resis-
tance, whilst maintaining the activity and stability of such proteinaceous structures. Utilising the increase in skin
temperature during infection, the truncated bacteriophage endolysin CHAPK and the staphylococcal bacteriocin
lysostaphin have been co-administered in a thermally triggered manner from Poly(N-isopropylacrylamide)
(PNIPAM) nanoparticles. The thermoresponsive nature of the PNIPAM polymer has been employed in order to
achieve the controlled expulsion of a synergistic enzybiotic cocktail consisting of CHAPK and lysostaphin. The
point at which this occurs is modiﬁable, in this case corresponding to the threshold temperature associated
with an infected wound. Consequently, bacterial lysis was observed at 37 °C, whilst growth was maintained at
the uninfected skin temperature of 32 °C.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Staphylococcus aureus (S. aureus) is a frequent inhabitant of the
human skin ﬂora colonizing up to 30% of individuals at any given
time, primarily through nasal carriage [1]. Requiring a suitable portal
of entry into the body, the skin normally provides such a barrier to pro-
gressive infection. However a breach in the skin, often as a result of a
scratch, cut or burn provides a suitable infection point for the opportu-
nistic bacteria. S. aureus is the leading cause of skin and soft tissue infec-
tions (SSTI) across all continents, thus resulting in both delayed wound
healing and further systemic infections, such as sepsis, osteomyelitis
and endocarditis [2]. With the discovery of staphylococcal drug resis-
tance and the subsequent global epidemic that methicillin resistant S.
aureus (MRSA) has become, the need to source alternative treatment
has become paramount. Hospital acquired MRSA (HA-MRSA) has a
mortality rate twice that of its methicillin susceptible counterpart, ands).
. This is an open access article underis more than twice as expensive to treat [3]. Furthermore, the isolation
of these ‘super-bugs’ is not conﬁned to thehospital setting. Indeed, com-
munity acquired MRSA (CA-MRSA) is proving an equal challenge to cli-
nicians worldwide [4].
Bacteriophage (phage), (the naturally occurring parasitic viruses of
bacteria, able to infect and destroy bacterial cells) were ﬁrst utilised as
a treatment to infection in the 1930s within the former Soviet Union.
Despite the continued development of phage products throughout the
Cold War, bacteriophage therapy was largely disregarded in the West
from under the relative comfort of the antibiotic blanket. However,
the alarming rise inmulti-drug resistance (MDR) in recent times has re-
generated interest in phage therapy [5]. One of the main disadvantages
associated with the use of whole phage to treat infection is the viral na-
ture of the phage itself. Containing a vast amount of genetic material,
temperate phage have been known to increase the virulence of certain
species of bacteria through transduction, an example of which includes
the bacterial acquisition of the gene encoding the Panton Valentine Leu-
cocidin toxin, causing ‘scalded skin syndrome’ [6].Whilst this is selected
against when sourcing phage for treatment, the regulation and control
of suitable virulent phage for clinical use is often timely and uncertain.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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thesised by phage infected bacterial cells) are utilised in the end stages
of phage infection. Lysins are capable of destroying the bacterial cell
wall through digestion of the peptidoglycan polymer, resulting in cell
death through osmolysis [7]. The isolation of these hydrolases has the
potential to overcome many issues surrounding the use of whole
phage. As hydrolytic enzymes, they retain speciﬁcity without affecting
commensal ﬂora, are capable of rapid bacterial lysis, are unlikely to en-
counter resistance owed to the essential bacterial binding sites and they
do not contain transducible genetic information [8]. The speciﬁc mech-
anism of action of these endolysins is discussed elsewhere [9].
Endolysins demonstrating activity towards both Gram-positive and
Gram-negative bacteria have been isolated and characterised, including
lysins active against Acinetobacter baumanni, Bacillus anthracis, Strepto-
coccus pyogenes and in some cases active against both Gram-positive
and –negative bacteria simultaneously [10–12]. The phage endolysin
designated LysK isolated from the staphylococcal bacteriophage K has
been shown to have potent antimicrobial activity against a range of
staphylococci includingMRSA [13]. LysK has been truncated to its single
catalytic domain, a cysteine, histidine-dependent aminohydrolase/pep-
tidase (CHAPK). This single domain, 18.6 kDa antimicrobial enzyme has
been fully characterised and has demonstrated retention of lytic activity
in vitro, in vivo and against staphylococcal bioﬁlms [14–16].
Another class of potential alternative antimicrobials are bacteriocins.
Lysostaphin, a 26.8 kDametalloendopeptidase is produced naturally by
Staphylococcus simulans [17]. Consisting of a single lytic domain (glycyl-
glycine M23 endopeptidase), lysostaphin demonstrates potent
antistaphylococcal activity through cleavage of the pentaglycine cross-
bridges within the peptidoglycan of the bacterial cell wall. Active
against a multitude of antibiotic susceptible, intermediate and resistant
strains of bacteria, lysostaphin exhibits synergistic behaviour with mul-
titude of antibiotics, phage lysins and antimicrobial peptides [18–20].
Successful application of lysostaphin has been demonstrated in cases
of ocular infection, osteitis and endocarditis [21–23].
Despite the discovery and development of new potential antimicro-
bial candidates, the mode of delivery of any such pharmacologically ac-
tive substance remains equally as important as the discovery itself.
Ensuring activity, stability and dosage conditions are correct (especiallyFig. 1. SEM images of non-woven polypropylene fabric (A) Untreated (B) Following PNIPAM n
Nanoparticles attached to the surface of a polypropylene ﬁbre.when considering biological material), is crucial to successful adminis-
tration in order to maximise the therapeutic beneﬁt and to reduce any
potential side effects. The triggered release of a therapeutic agent
(smallmolecule, protein or virus)may rely on a variety of external stim-
uli in order to release the active cargo, including pH, temperature, ultra-
sound, magnetism or biomarker signals [24,25]. Utilising the difference
between the healthy and the diseased state may provide certain condi-
tions whereby treatment can be administered in a controlled fashion.
Consequently, high local concentrations are achieved only in the speciﬁc
location required. When considering treatment of bacterial infection,
preventing the administration of unnecessary or sub-lethal concentra-
tions of an antibiotic or antimicrobial agent is crucial in preventing the
continued development of antibiotic resistance [26].
Poly(N-isopropylacrylamide) (PNIPAM) has been widely investigat-
ed as a triggered drug release vehicle [27]. As a thermoresponsive poly-
mer, PNIPAM undergoes a reversible, entropically driven phase
transition at a lower critical solution temperature (LCST), resulting in
the expulsion of water and a subsequent change in polymer volume.
The LCST of PNIPAM and its associated structures (nanoparticles, mi-
celles, nanogels etc.) can be manipulated through control of polymer
concentration, copolymers and surfactants. Through adjusting the
LCST to that of a clinically relevant temperature, PNIPAM has been ex-
tensively investigated in awide range of biomedical applications includ-
ing cancer therapy, wound healing, bioscaffolding and cell cultivation
[28–31].
In previous studies, PNIPAM nanoparticles were formulated with
allylamine for the controlled release of Bacteriophage K, which demon-
strated potent antistaphyloccal activity through the thermally con-
trolled collapse of the nanoparticles [32]. However in this study, phage
virions were replaced with a synergisitic enzybiotic cocktail. Allylamine
was used in order to adjust the LCST to a biologically relevant tempera-
ture of 34 °C, which is indicative of an infectedwound. A bacterial infec-
tion of a wound as been shown to present as an elevation in skin
temperature of around 3.6 °C (demonstrated in infected leg ulcers), in
comparison to the surface temperature of approximately 32 °C seen in
healthy skin [33]. PNIPAM nanoparticles were anchored to non-woven
polypropylene to simulate a wound dressing using plasma deposited
maleic anhydride and free amine groups from allylamine. Plasmaanoparticle attachment (C) Polymeric matrix seen dispersed within the ﬁbre network (D)
Fig. 3. Synergy analysis of CHAPK (MIC = 64 μg/ml) (ordinate) and lysostaphin (MIC =
0.125 μg/ml) (abscissa).
Fig. 2. Comparison of the initial rate of bacterial cell lysis by: (A) CHAPK (B) lysostaphin.
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mented elsewhere [34–36]. As a representative bacterial isolate,
MRSA252 was chosen, which is a HA-MRSA bacterium belonging to
the clinically relevant epidemic MRSA-16 clone (EMRSA-16), and con-
sidered endemic in the majority of UK hospitals [37].
2. Materials and methods
2.1. Materials
N-isopropylacrylamide, allylamine, ethylene-glycol diacrylate, sodi-
um persulfate, sodium dodecylsulfate (SDS), phosphate buffered saline
(PBS) tablets (pH 7.4), vancomycin hydrochloride from Streptomyces
orientalis and maleic anhydride were all purchased from Sigma-Aldrich
(Poole, Dorset, UK).
Lysostaphin from Staphylococcus simulans, Tryptic Soy Broth (TSB)
and Tryptic Soy Agar (TSA) were purchased from Sigma-Aldrich
(Poole, Dorset, UK). Coomassie (Bradford) Protein Assay Kit was pur-
chased from Pierce Scientiﬁc. MRSA 252 was sourced from a bacterial
strain collection belonging to the Biophysical Chemistry Research
Group housed at the University of Bath.
2.2. Material preparation
2.2.1. PNIPAM nanoparticle synthesis, plasma deposition and surface
grafting
Particles were synthesised via precipitation polymerisation and an-
chored onto of non-woven polypropylene (2 × 2 cm) squares via plas-
ma deposited maleic anhydride as previously described [32], the only
modiﬁcation being an increase in the surface grafting duration from 1
to 24 h. Following surface attachment, samples were washed in DI
water, air dried and kept under aseptic conditions prior to enzyme
addition.
2.2.2. Electron microscopy
Samples were prepared as above, freeze dried, sputter coated with
gold and imaged via a Scanning Electron Microscope (SEM) (JEOL
JSM6480LV operated at 10 KV).
2.3. Microbiology
2.3.1. Bacteria and growth conditions
MRSA 252 was taken from freezer stock (stored as a 15% (v/v) glyc-
erol at−80 °C), streaked across a TSA culture platewith a loop spreader
and incubated at 37 °C overnight in order to obtain single colonies.Bacterial cultures were prepared by inoculating 10ml TSB with a single
colony and incubating at 37 °C with agitation overnight.
2.3.2. CHAPK production
CHAPK production was performed as previously described [16].
Brieﬂy, the truncated lysin CHAPK was previously cloned and expressed
using a pQE60 vector (Qiagen) in Escherichia coli (E. coli) XL1-Blue [38].
This recombinant E. coli was grown at 37 °C with shaking. Protein ex-
pression was achieved by inducing the cells with Isopropyl β-D-1-thio-
galactopyranoside (IPTG). After which, the cells were lysed and active
CHAPK was puriﬁed to N90% homogeneity by cation exchange chroma-
tography and quantiﬁed via the Bradford assay [39].
2.3.3. Minimum inhibitory concentration (MIC)
MICs for both CHAPK and lysostaphin were determined by the clas-
sical microdilution broth method, conducted according to the Clinical
and Laboratory Standards Institute (CLSI) guidelines [40,41]. Brieﬂy,
MRSA 252 cells at 7 × 105 colony forming units per millilitre (CFU/ml)
were added to wells containing varying concentrations of CHAPK (64–
1 μg/ml) and lysostaphin (0.25–0.004 μg/ml) in a microtitre plate. The
plate was then incubated for 18 h with shaking in a micro-plate reader
(SPECTROstar Omega, BMG LABTECH) and bacterial growth monitored
Fig. 4. SEM images of untreated and antibiotic treated S. aureusMRSA 252 cells (A) cells exposed to DI water (control) (B) cells exposed to 2 × MIC (12.5 μg/ml) vancomycin. 10 min
incubation time. Cell division observed in both cases.
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ducted in triplicate both at 37 °C and 32 °C. Deionised (DI) water was
used to make enzyme stock solutions and for control experiments.
2.3.4. Turbidity reduction assays
The in vitro activity of both CHAPK and lysostaphin was assessed ac-
cording to the rate of bacterial cell lysis. MRSA 252 cells at 7 × 105 CFU/
ml were grown to an OD of 0.5, centrifuged at 4000 rpm for 20 min at
4 °C, washed twice and resuspended in PBS to reattain an OD of 0.5. A
range of CHAPK and lysostaphin solutions were prepared in deionised
water with concentrations relative to their MIC (0–16%) in order to as-
sess enzyme activity in the presence of excess substrate: 100 μl of en-
zyme solution was added to 100 μl of bacterial solution in a microtitre
plate in triplicate, the plate was shaken for 5 s to ensure sufﬁcientC 
A 
Fig. 5. SEM images of S. aureusMRSA 252 cells treated with antimicrobial enzymes (A) At MIC:
CHAPK + 0.031 μg/ml lysostaphin. 10 min incubation time.mixing and the reduction in OD at 600 nm over 5 min was monitored
using a micro-plate reader at either 37 °C and 32 °C. Control experi-
ments were undertaken using deionised water in place of either
CHAPK or lysostaphin.2.3.5. Synergy
Synergy was assessed according to the checkerboard assay [42].
Brieﬂy, 100 μl of 7 × 105 CFU/ml MRSA 252 was added to each well of
an 8 × 8 section of a 96 well microtitre plate containing varying ratios
of CHAPK: lysostaphin, ranging from 64 to 1 μg/ml CHAPK and 0.25–
0.004 μg/ml lysostaphin. The plate was incubated at 37 °C for 24 hwith-
out shaking and bacterial growth assessed visually. Synergy was con-
ﬁrmed by observation of wells with no visible bacterial growth atD
B 
64 μg/ml CHAPK (B) At MIC 0.125 μg/ml lysostaphin (C + D) Sub-individual MIC 8 μg/ml
Fig. 7. Comparison of bacterial survival at 32 °C and 37 °C for PNIPAM nanoparticle
entrapped CHAPK/lysostaphin cocktail, relative to PNIPAM nanoparticles without
enzymatic cocktail (control) **** p b 0.0001.
Table 1
Concentration of protein added to modiﬁed fabric, residual non-adsorbed protein and
hence encapsulated protein concentration.
Protein added
μg/ml
Residual non-absorbed protein
μg/ml
Encapsulated protein
μg/ml
88.0 ± 9.2 38.3 ± 21.5 49.7 ± 23.4
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antimicrobials.
2.3.6. Electron microscopy
Bacterial samples were grown on Melinex® ﬁlm overnight in 5 ml
TSB at 37 °C with minimal agitation (70 rpm). The volume of growth
media was adjusted to 2 ml and exposed to either 64 μg/ml CHAPK,
0.125 μg/ml lysostaphin, a combination of 8 μg/ml + 0.031 μg/ml
lysostaphin or DI water (control) for 10 min at 37 °C. Samples were
then ﬁxed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer,
postﬁxed in aqueous 1% osmium tetroxide, dehydrated in an acetone
series (50–100%) and chemically dried in hexamethyldisilazane
(HMDS). Samples were sputter coated with a thin layer of chromium
and imaged using a Field Emission Scanning Electron Microscope
(FESEM) (JEOL JSM6301F operating at 5 KV).
2.4. Controlled release experiments
2.4.1. Addition of CHAPK and lysostaphin to anchored nanoparticles
A cocktail consisting of 80 μg/ml CHAPK and 0.31 μg/ml lysostaphin
(10 times the concentration shown to generate synergistic inhibition)
was incorporated into the anchored gel matrix via soaking the dried
gel modiﬁed polypropylene fabric in 500 μl of enzyme solution for 2 hFig. 6. Plate analysis of S. aureusMRSA 252 survival and growth - (A) PNIPAM control at 32 °C
lysostaphin at 37 °C.at room temperature (20 °C). The fabric was washed in DI water and
air dried. Control experiments were undertaken using DI water in
place of enzyme solution. In order to estimate protein loading of the
nanoparticles, the Bradford assay was used to quantify total protein
concentration both in the soaking solution (as conﬁrmation of synergy(B) PNIPAM/CHAPK/lysostaphin at 32 °C (C) PNIPAM control at 37 °C (D) PNIPAM/CHAPK/
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washed post soaking. All experiments were performed in triplicate
and corrected against control swatches (soaked in DI water) in order
to eliminate any non-protein associated solution absorbance. An aver-
age blank reading was used to baseline correct all absorbance readings,
using DI water only. The residual protein concentration post washing
was subtracted from the initial soaking concentration in order to esti-
mate loading efﬁciency (LE) according to the following equation:
LE %ð Þ ¼ total protein added−protein in washingsð Þ
total protein added
 100
2.4.2. Thermal release of CHAPK/lysostaphin cocktail from grafted pnipam
nanoparticles
Polypropylene-nanoparticle swatches incorporating the enzybiotics
were soaked individually in 250 μl of MRSA 252 of ﬁxed concentration
(1.2 ×108 CFU/ml in PBS) at either 32 °C or 37 °C for 30min. Each square
of fabric was then removed from solution and placed into 24.75 ml DI
water (diluting the original solution volume 100 fold) alongside any re-
sidual liquid that had not been soaked up by the fabric. The 25 ml cul-
ture tube containing the fabric swatch was vortexed to remove any
bacteria attached to the fabric and the solution from each tube was di-
luted and plated (in triplicate) on TSA plates and incubated at 37 °C
overnight. Plates were assessed the following day for growth and any
colonies counted. Control experiments were undertaken using the
swatches without enzyme and each individual experiment was repeat-
ed 6 times.
3. Results and discussion
3.1. Material analysis
3.1.1. PNIPAM nanoparticle characterisation and surface grafting
The PNIPAMnanoparticles have been characterised by dynamic light
scattering (DLS) and according to zeta potential analysis as reported in a
previous study [32]. The LCST of the nanoparticles was shown to be
transitional but clearly deﬁnitive at 34 °C, manifesting as a change in
the hydrodynamic radius from 400 nm ± 50 nm in the expanded
state (b33 °C), to 170 nm ± 30 nm in the collapsed state (N35 °C).
Therefore the collapse of the nanoparticles and subsequent release of
the enzybiotic cargo is targeted to occur only at a higher temperature
associated with bacterial wound infection (around 36 °C), whilst re-
maining intact and preventing the release of the antimicrobial payload
at temperatures indicative of an uninfectedwound (around 32 °C). Suc-
cessful deposition ofmaleic anhydride onto the non-woven polypropyl-
ene as anchor points for the nanoparticles was conﬁrmed by Fourier
Transform Infrared Spectroscopy (FT-IR) (S1-Supporting Information)
as previously described.
3.1.2. Electron microscopy
SEM images indicated the incorporation of the PNIPAMnanoparticle
solution to non-woven polypropylene following surface activationwith
plasma depositedmaleic anhydride and wash steps, as shown in Fig. 1A
and B. The large polymer webs (Fig. 1B) seen throughout the ﬁbre ma-
trix, appear to consist of individual nanoparticles held together by the
polymeric sheets (Fig. 1C). The nanoparticles are of varying sizes
encompassing both the swollen and the collapsed state, possibly as a re-
sult of the freeze drying during the sample preparation. Fig. 1D shows
the surface attachment of individual nanospheres.
3.2. Microbiological analysis
3.2.1. Minimum inhibitory concentration (MIC)
The MIC was determined at both 32 °C and 37 °C as 64 μg/ml and
0.125 μg/ml, for CHAPK and lysostaphin, respectively, illustrating nochange in the ability of either enzyme to prevent bacterial growthwith-
in this temperature range.3.2.2. Turbidity reduction and rate of cell lysis
The rate at which both CHAPK and lysostaphin catalyse cell lysis was
determined by assessing the reduction in turbidity (OD) of a bacterial
suspension over the course of 60 s, deﬁned as the initial rate of reaction
(S2-Supporting Information). This was investigated at 32 °C (below the
LCST of the nanospheres) and at 37 °C (above the LCST), and at low con-
centrations of enzyme in order to prevent substrate concentration from
becoming a limiting factor. Initial rateswere calculated bymeans of tan-
gents and plotted as a function of enzyme concentration relative to the
MIC (Fig. 2A and B).
From these results it can be seen that CHAPK is capable of eliciting a
rapid reduction in turbidity (associated with bacterial cell lysis) which
follows a standard dose response at both temperatures, whilst slightly
more linear at 32 °C. There is a small difference in the initial rate of re-
action at the two temperatures, more noticeably at higher concentra-
tions of CHAPK but not to such an extent that indicates enzyme
activity is substantially hindered at the lower temperature. However it
appears that lysostaphin is unable to initiate a substantial degree of
cell lysis (even at the highest concentrations) in such a short timeframe
despite having a very low overall MIC, with values being similar to that
of the control and demonstrating little temperature associated effect.
This is in keeping with previous studies whereby CHAPK exhibited a
greater reduction in turbidity over a 5 min period when compared to
lysostaphin of the same absolute concentration (independent of MIC)
[14].3.2.3. Assessment of synergistic behaviour
Synergy was assessed both visually (non-growth of bacteria in well
plate) and via calculation of fractional inhibitory concentration (FIC),
taking the value of the MIC of the enzymes in combination, divided by
the MIC of the individual enzyme. To achieve strong synergy the sum
of the two FICs (ΣFIC = FICA + FICB) must be b0.5 [43]. As shown in
Fig. 3, synergy is indicated across the microtitre plate, at a range of dif-
ferent concentrations and conﬁrmed in a total of 11 wells with FICs
ranging from 0.144 (well G5) to 0.378 (well C5). A combination of
8 μg/ml CHAPK and 0.031 μg/ml lysostaphin was chosen as a concentra-
tionwhichdemonstrates a strong synergistic combination (correspond-
ing to a 3 fold reduction in theMIC of lysostaphin and a 4 fold reduction
in the MIC of CHAPK), in order to utilise the ability of lysostaphin to in-
hibit bacterial growth at low concentration, together with an increased
rate of cell lysis exhibited by CHAPK.3.2.4. Electron microscopy
Untreated MRSA cells exhibited uniformity in the presentation
of their cell morphology as shown in Fig. 4A, active cell division
was also observed. Cells treated with vancomycin at twice the MIC
(12.5 μg/ml) for 10 min as shown in Fig. 4B, did not present any
change in their surface morphology or exhibit any visible membrane
damage.
Cells treated with CHAPK (at the MIC) (Fig. 5A) show some surface
damage and slightly more extracellular debris when compared to the
control (Fig. 4A); however the majority of the cells appear unaffected.
When evaluating cells exposed to lysostaphin at the MIC (Fig. 5B),
they are comparable in appearance to those in the control group. This
is in keeping with the established rate of lysis observed in solution,
with CHAPK beingmuch faster in eliciting a response. The synergistic ef-
fect of the cocktail of the two enzymes can be clearly observed in Fig. 5C:
blebbing (protrusion of the plasma membrane) was seen (red arrow)
and a high degree of debris. Fig. 5D also shows clear evidence of cell
lysis by the enzybiotic cocktail.
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Fabric swatches with surface anchored PNIPAM nanoparticle gel
were soaked in an enzyme solution consisting of 80 μg/ml CHAPK and
0.31 μg/ml lysostaphin (10 times the synergy MIC), this was conﬁrmed
using the Bradford assay. The unencapsulated, residual protein concen-
tration in solution post soaking and washing was calculated (Table 1),
thus giving an estimated loading concentration of 49.7 ± 23.4 μg/ml
or approximately 56%. As the effective synergistic combination of the
bactericidal enzymes equates to approximately 8 μg/ml, even at the
lower limit of this estimate, this is over 3 times the concentration of
the cocktail required to inhibit bacterial growth.
PNIPAM nanoparticles are able to deliver an enzymatic formulation
in a temperature controlled manner as shown by evaluating the differ-
ence in cell count post incubation at temperatures both above and
below the LCST. Samples plated after incubation at 32 °C demonstrate
very little difference in the number of colonies between the controls
(nanoparticles without enzybiotic cocktail) (Fig. 6A) and the samples
containing the enzybiotic cocktail (Fig. 6B). The control experiments
also conﬁrm that the nanoparticles alone do not affect the bacteria.
Whereas samples tested at 37 °C indicate a drastic decrease in the num-
ber of viable cells post treatment (Fig. 6D). Fig. 6C conﬁrms that the col-
lapse of the nanoparticles above the LCST does not affect the survival of
the bacteria, being comparable to the controls undertaken at 32 °C.
Quantitative analysis (colony counting) showed a signiﬁcant differ-
ence in the number of viable cells at the two temperatures
(p ≤ 0.0001, Student's t-test). Whilst there is a relatively small change
in the number of CFU/ml between the control and the experimental
sample at 32 °C, this is not unreasonable when taking into account pos-
sible passive diffusion or leaching of the enzymes from the particles.
Nonetheless, when compared to samples incubated at 37 °C there is a
clear difference in survival, manifesting as a N4 log reduction in CFU/
ml compared to b1 log difference at 32 °C (Fig. 7).4. Conclusion
In summary this study demonstrates a new and previously unre-
ported application of a novel enzybiotic cocktail for the thermally trig-
gered control of Staphylococcus aureus. As potentially viable
alternatives to antibiotic therapy, the use of enzybiotics may indicate a
possible future treatment for drug resistant bacterial infection. Through
exploitation of the ability of lysostaphin to inhibit bacterial growth at
very low concentration, and the fast acting nature of the bacteriophage
encoded endolysin CHAPK, the two antimicrobial enzymes have been
shown to work synergistically in the inhibition and subsequent lysis of
bacterial cells, demonstrating a faster response time when compared
to the current antibiotic of choice for the treatment of MRSA. Moreover,
restricting the administration of such antimicrobials by means of an ex-
ternal trigger (in this case an increase in skin temperature associated
with infection), limits the possibility of the development of resistance
through prevention of any sub-lethal selection pressure. Through ex-
ploitation of the thermoresponsive behaviour of PNIPAM, nanoparticles
were employed as a drug delivery system capable of releasing their an-
timicrobial cargo at a biologically relevant temperature indicative of in-
fection. Which, when compared to the same system containing whole
phage, the use of an enzybiotic cocktail which is not self-replicating
but relies solely on successful diffusion from the polymer matrix and
full retention of stability, the results are a promising step forward in
the controlled release of an alternative antimicrobial formulation,whilst
avoiding any issues associated with the administration of whole phage
[32]. Although the clinical indication of our delivery system would be
chronic wound infection via utilisation of a dressing/bandage concept,
the technology presented here offers the possibility of infection control
through use of enzybiotics for a range of conditions owing to the proven
stability and retention of activity of the proteins.Acknowledgements
The authors wish to acknowledge the Biotechnology and Biological
Sciences Research Council (BBSRC) (BB/K011995/1) and Public Health
England for funding this work. Special thanks to Diana Lednitzky for
her help with the SEM and Charlotte Hind for her help with microbiol-
ogy. All data created during this research is openly available from the
University of Bath data archive at http://doi.org/10.15125/BATH-00247.
Appendix A. Supplementary data
FT-IR spectra of non-woven polypropylene before and after plasma
deposition of maleic anhydride. Reduction in turbidity of planktonic
MRSA 252 by CHAPK at 37 °C with tangents ﬁtted for calculation of ini-
tial rate of reaction. Supplementary data associated with this article can
be found in the online version, at 10.1016/j.jconrel.2016.11.030.References
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